10 results about "Teriflunomide" patented technology

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The invention discloses an application of teriflunomide in preparation of a medicine for preventing and / or treating recurrent / refractory immune thrombocytopenia. According to the traditional Chinese medicine composition, the problem that relapse is difficult to treat in an existing ITP treatment scheme is solved, and the 24-week continuous remission rate of treating ITP patients with relapse and relapse difficult to treat can reach 50%. It is found for the first time that teriflunomide can be used as a candidate drug for ITP treatment to treat immune thrombocytopenia, and the teriflunomide has a good application prospect in the aspect of preventing or treating immune thrombocytopenia, especially in the aspect of recurrent / refractory immune thrombocytopenia.

The invention provides application of teriflunomide in preparation of a medicine for treating ovarian cancer and the medicine. The application provided by the invention can provide an effective, safe and drug-resistant ovarian cancer treatment drug for further treatment of ovarian cancer.

The present invention relates to a film coated tablet comprising teriflunomide, wherein the tablet comprising calcium stearate as lubricant and teriflunomide has a d (0.5) particle between 1 μm and 18 μm. Further the present invention discloses a method for the preparation of said tablet.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Provided here are methods for treating a cytokine storm in a subject. One such method includes the administration of a therapeutically effective amount of an Insulin-like Growth Factor (IGF-1), a Ca2+-release-activated Ca2+ (CRAC) channel inhibitor, or combinations thereof. Methods include treatment of acute lung injury or acute kidney injury with a therapeutically effective amount of 3,5-bis(trifluoromethyl) pyrazole derivative or teriflunomide, either individually or in combination with IGF-1.

The invention relates to develop a pharmaceutical tablet composition for oral administration, comprising Teriflunomide or а pharmaceutically ассерtаblе salt thereof, and а method for the preparation of said tablet with obtaining teriflunomide containing granules using wet granulation method and using a specific particle size distribution of Teriflunomide granules to provide content uniformity of tablets.